The clinical toxicology of the designer “party pills” benzylpiperazine and trifluoromethylphenylpiperazine

References

• Johnstone AC, Lea RA, Brennan KA, Schenk S, Kennedy MA, Fitzmaurice PS. Benzylpiperazine: a drug of abuse? J Psychopharmacol 2007; 21:888–894.
   PubMed Web of Science ®Google Scholar
• Glennon RA, McKenney JD, Young R. Discriminative stimulus properties of the serotonin agonist 1-(3-trifluoromethylphenyl) piperazine (TFMPP). Life Sci 1984; 35:1475–1480.
   PubMed Web of Science ®Google Scholar
• Caccia S, Fong MH, Urso R. Ionization constants and partition coefficients of 1-arylpiperazine derivatives. J Pharm Pharmacol 1985; 37:567–570.
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. British National Formulary 60. London: Pharmaceutical Press; 2010.
   Google Scholar
• Bye C, Munro-Faure AD, Peck AW, Young PA. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973; 6:163–169.
   PubMed Web of Science ®Google Scholar
• Campbell H, Cline W, Evans M, Lloyd J, Peck AW. Comparison of effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1973; 6:170–176.
   PubMed Web of Science ®Google Scholar
• Magyar K. Pharmacokinetic aspects of the mode of action of Egyt-475, a new antidepressant agent. Pol J Pharmacol Pharm 1987; 39:107–112.
   PubMedGoogle Scholar
• Magyar K, Fekete MI, Tekes K, Torok TL. The action of trelibet, a new antidepressive agent On [H-3] noradrenaline release from rabbit pulmonary artery. Eur J Pharmacol 1986; 130:219–227.
   PubMed Web of Science ®Google Scholar
• Tekes K, Tothfalusi L, Malomvolgyi B, Herman F, Magyar K. Studies on the biochemical-mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm 1987; 39:203–211.
   PubMedGoogle Scholar
• Malomvolgyi B, Tothfalusi L, Tekes K, Magyar K. Comparison of serotonin agonistic and antagonistic activities of a new antidepressant agent trelibet (Egyt-475) and its metabolite EGYT-2760 on isolated rat fundus. Acta Physiol Hung 1991; 78:201–209.
   PubMed Web of Science ®Google Scholar
• Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 2005; 118:U1784.
   Google Scholar
• Gee P, Fountain J. Party on? BZP party pills in New Zealand. N Z Med J 2007; 120:U2422.
   Google Scholar
• Lin JC, Bangs N, Lee H, Kydd RR, Russell BR. Determining the subjective and physiological effects of BZP on human females. Psychopharmacology (Berl) 2009; 207:439–446.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule. Fed Regist 2004; 69:12794–12797.
   Google Scholar
• Brennan KA, Lake B, Hely LS, Jones K, Gittings D, Colussi-Mas J, et al. N-benzylpiperazine has characteristics of a drug of abuse. Behav Pharmacol 2007; 18:785–790.
   PubMed Web of Science ®Google Scholar
• Sheridan J, Butler R, Wilkins C, Russell B. Legal piperazine-containing party pills – a new trend in substance misuse. Drug Alcohol Rev 2007; 26:335–343.
   PubMed Web of Science ®Google Scholar
• Wilkins C, Sweetsur P, Girling M. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev 2008; 27:633–639.
   PubMed Web of Science ®Google Scholar
• Wilkins C, Sweetsur P. Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: a case of effective industry self-regulation? Int J Drug Policy 2010; 21:86–90.
   PubMed Web of Science ®Google Scholar
• Sheridan J, Butler R. “They’re legal so they’re safe, right?” What did the legal status of BZP-party pills mean to young people in New Zealand? Int J Drug Policy 2010; 21:77–81.
   PubMed Web of Science ®Google Scholar
• Fisher D. Human guinea pigs for party pill. New Zealand Herald. Auckland; 27 November 2005.
   Google Scholar
• Misuse of Drugs (Classification of BZP) Amendment Act 2008 No 5, Public Act. 2008. http://www.legislation.govt.nz/act/public/2008/0005/latest/DLM1152221.html. 2008. Accessed 23 October 2010.
   Google Scholar
• Jones CN, Howard JL, McBennett ST. Stimulus properties of antidepressants in the rat. Psychopharmacology (Berl) 1980; 67:111–118.
   PubMed Web of Science ®Google Scholar
• Cunningham KA, Appel JB. Possible 5-hydroxytryptamine 1 (5HT1) receptor involvement in the stimulus properties of 1-(m-trifluoromethylphenyl)piperazine (TFMPP). J Pharmacol Exp Ther 1986; 237:369–377.
   PubMed Web of Science ®Google Scholar
• Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. Effects of “Legal X” piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci 2004; 1025:189–197.
   PubMed Web of Science ®Google Scholar
• Meririnne E, Kajos M, Kankaanpaa A, Seppala T. Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin Pharmacol Toxicol 2006; 98:346–350.
   PubMed Web of Science ®Google Scholar
• Oberlander C, Euvrard C, Dumont C, Boissier JR. Circling behavior induced by dopamine releasers and-or uptake inhibitors during degeneration of the nigrostriatal pathway. Eur J Pharmacol 1979; 60:163–170.
   PubMed Web of Science ®Google Scholar
• Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’). Neuropsychopharmacology 2005; 30:550–560.
   PubMed Web of Science ®Google Scholar
• Szucks Z, Szentendrei T, Fekete MI. The effect of EGYT-475 (trelibet) and its metabolites on the potassium-stimulated H-3 noradrenaline release from cortical slices of rat-brain. Pol J Pharmacol Pharm 1987; 39:185–193.
   PubMedGoogle Scholar
• Herndon JL, Pierson ME, Glennon RA. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine. Pharmacol Biochem Behav 1992; 43:739–748.
   PubMed Web of Science ®Google Scholar
• Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 2005; 77:161–168.
   PubMed Web of Science ®Google Scholar
• Pettibone DJ, Williams M. Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 1984; 33:1531–1535.
   PubMed Web of Science ®Google Scholar
• Auerbach SB, Rutter JJ, Juliano PJ. Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis. Neuropharmacology 1991; 30:307–310.
   PubMed Web of Science ®Google Scholar
• Auerbach SB, Kamalakannan N, Rutter JJ. TFMPP and RU24969 enhance serotonin release from rat hippocampus. Eur J Pharmacol 1990; 190:51–57.
   PubMed Web of Science ®Google Scholar
• Robertson DW, Bloomquist W, Wong DT, Cohen ML. mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors. Life Sci 1992; 50:599–605.
   PubMed Web of Science ®Google Scholar
• McKenney JD, Glennon RA. TFMPP may produce its stimulus effects via a 5-HT1B mechanism. Pharmacol Biochem Behav 1986; 24:43–47.
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Effects of benzylpiperazine derivatives on the acute effects of 3,4-methylenedioxymethamphetamine in rat brain. Neurosci Lett 1993; 152:17–20.
   PubMed Web of Science ®Google Scholar
• Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR. Pharmacokinetics of ‘party pill’ drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci Int 2009; 186:63–67.
   PubMed Web of Science ®Google Scholar
• Antia U, Tingle MD, Russell BR. In vivo interactions between BZP and TFMPP (party pill drugs). N Z Med J 2009; 122:29–38.
   PubMedGoogle Scholar
• Antia U, Tingle MD, Russell BR. Validation of an LC–MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J Forensic Sci 2010; 55:1311–1318.
   PubMed Web of Science ®Google Scholar
• Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography–mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 773:35–46.
   PubMed Web of Science ®Google Scholar
• Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 2004; 39:235–244.
   Google Scholar
• Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, et al. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. J Anal Toxicol 2006; 30:38–43.
   PubMed Web of Science ®Google Scholar
• Staack RF, Fritschi G, Maurer HH. New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J Mass Spectrom 2003; 38:971–981.
   PubMed Web of Science ®Google Scholar
• Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, et al. Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats. Xenobiotica 2005; 35:107–116.
   PubMed Web of Science ®Google Scholar
• Antia U, Tingle MD, Russell BR. Metabolic interactions with piperazine-based ‘party pill’ drugs. J Pharm Pharmacol 2009; 61:877–882.
   PubMed Web of Science ®Google Scholar
• Murphy M, Antia U, Chang HY, Han JY, Ibrahim U, Tingle MD, Russell BR. Party pills and drug–drug interactions. N Z Med J 2009; 122:3564.
   Google Scholar
• Caccia S, Conti I, Notarnicola A. In-vivo metabolism in the rat and mouse of antrafenine to 1-m-trifluoromethylphenylpiperazine. J Pharm Pharmacol 1985; 37:75–77.
   PubMed Web of Science ®Google Scholar
• Gee P, Richardson S. Researching the toxicity of party pills. Nurs N Z 2005; 11:12–13.
   PubMedGoogle Scholar
• Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila) 2008; 46:802–807.
   PubMed Web of Science ®Google Scholar
• Wikström M, Holmgren P, Ahlner J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol 2004; 28:67–70.
   PubMed Web of Science ®Google Scholar
• Butler RA, Sheridan JL. Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduct J 2007; 4:18.
   PubMedGoogle Scholar
• Theron Y, Jansen K, Miles J. Benzylpiperizine-based party pills’ impact on the Auckland City Hospital Emergency Department Overdose Database (2002–2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. N Z Med J 2007; 120:U2416.
   Google Scholar
• Nicholson TC. Prevalence of use, epidemiology and toxicity of ‘herbal party pills’ among those presenting to the emergency department. Emerg Med Australas 2006; 18:180–184.
   PubMedGoogle Scholar
• Lee MO, Vivier PM, Diercks DB. Is the self-report of recent cocaine or methamphetamine use reliable in illicit stimulant drug users who present to the emergency department with chest pain? J Emerg Med 2009; 37:237–240.
   PubMed Web of Science ®Google Scholar
• Kim MT, Hill MN. Validity of self-report of illicit drug use in young hypertensive urban African American males. Addict Behav 2003; 28:795–802.
   PubMed Web of Science ®Google Scholar
• Wilkins C, Girling M, Sweetsur P. The prevalence of use, dependency and harms of legal ‘party pills’ containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J Subst Use 2007; 12:213–224.
   Google Scholar
• Gee P, Jerram T, Bowie D. Multiorgan failure from 1-benzylpiperazine ingestion – legal high or lethal high? Clin Toxicol (Phila) 2010; 48:230–233.
   PubMed Web of Science ®Google Scholar
• Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, Jones AL. Collapse, reported seizure – and an unexpected pill. Lancet 2007; 369:1490.
   Google Scholar
• Poon WT, Lai CF, Lui MC, Chan AY, Mak TW. Piperazines: a new class of drug of abuse has landed in Hong Kong. Hong Kong Med J 2010; 16:75.
   Google Scholar
• Wood DM, Button J, Lidder S, Ramsey J, Holt DW, Dargan PI. Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). J Med Toxicol 2008; 4:254–257.
   PubMedGoogle Scholar
• Thompson I, Williams G, Caldwell B, Aldington S, Dickson S, Lucas N, et al. Randomised double-blind, placebo-controlled trial of the effects of the ‘party pills’ BZP/TFMPP alone and in combination with alcohol. J Psychopharmacol 2010; 24:1299–1308.
   PubMed Web of Science ®Google Scholar
• Austin H, Monasterio E. Acute psychosis following ingestion of ‘Rapture’. Australas Psychiatry 2004; 12:406–408.
   PubMedGoogle Scholar
• Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, Russell BR. Determining the subjective effects of TFMPP in human males. Psychopharmacology (Berl) 2010; 211:347–353.
   PubMed Web of Science ®Google Scholar
• Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N Z Med J 2006; 119:U1959.
   Google Scholar
• Harnett MA. Piperazine-based party drugs: case series of 73 poisonings [conference abstract]. Clin Toxicol (Phila) 2007; 45:373.
   PubMedGoogle Scholar
• Klaassen T, Pian KLH, Westenberg HGM, den Boer JA, van Praag HM. Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine. Psychiatry Res 1998; 79:207–212.
   PubMed Web of Science ®Google Scholar
• Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 2009; 39:210–271.
   PubMed Web of Science ®Google Scholar
• Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila) 2010; 48:675–694.
   PubMed Web of Science ®Google Scholar
• Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. Fatal brain oedema after ingestion of ecstasy and benzylpiperazine [German]. Dtsch Med Wochenschr 2001; 126:809–811.
   PubMed Web of Science ®Google Scholar
• Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) ingestion. QJM 2002; 95:431–437.
   PubMed Web of Science ®Google Scholar
• Elliott S, Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 2008; 32:172–177.
   PubMed Web of Science ®Google Scholar
• Elliott S, Woolacott H, Braithwaite R. The prevalence of drugs and alcohol found in road traffic fatalities: a comparative study of victims. Sci Justice 2009; 49:19–23.
   PubMed Web of Science ®Google Scholar
• Carter B. Coroner probes party pill link in New Year death. The New Zealand Herald. Auckland; 7 January 2007.
   Google Scholar
• Wright E, Davies R, Warne C. New killer drug alert as mortgage adviser dies. Sheffield Telegraph. Sheffield; 9 May 2009.
   Google Scholar
• Woodford G. Coroner calls for law change after man’s ‘party drug’ death. Nottingham Post. Nottingham; 28 May 2009.
   Google Scholar
• Hammer K. After club-goer’s death, Health Canada looks at BZP. The Globe and Mail. Toronto; 10 July 2008.
   Google Scholar
• McNamara S. 1-benzylpiperazine (BZP) abuse amongst attendees of the Drug Treatment Centre Board. Ir Med J 2009; 102:191.
   PubMedGoogle Scholar
• Vorce SP, Holler JM, Levine B, Past MR. Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS. J Anal Toxicol 2008; 32:444–450.
   PubMed Web of Science ®Google Scholar
• Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom 2003; 38:659–676.
   PubMed Web of Science ®Google Scholar
• Kulig K, Vale JA. Position paper: gastric lavage. J Toxicol Clin Toxicol 2004; 42:933–943.
   PubMed Web of Science ®Google Scholar
• Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: single-dose activated charcoal. Clin Toxicol (Phila) 2005; 43:61–87.
   PubMed Web of Science ®Google Scholar
• Krenzelok EP, McGuigan M, Lheureux P, Manoguerra AS. Position paper: ipecac syrup. J Toxicol Clin Toxicol 2004; 42:133–143.
   PubMedGoogle Scholar
• Downes MA, Healy P, Page CB, Bryant JL, Isbister GK. Structured team approach to the agitated patient in the emergency department. Emerg Med Australas 2009; 21:196–202.
   PubMed Web of Science ®Google Scholar
• Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003; 20:339–346.
   PubMed Web of Science ®Google Scholar
• Whelan KR, Dargan PI, Jones AL, O’Connor N. Atypical antipsychotics not recommended for control of agitation in the emergency department. Emerg Med J 2004; 21:649.
   Google Scholar
• Dubin WR, Weiss KJ, Dorn JM. Pharmacotherapy of psychiatric emergencies. J Clin Psychopharmacol 1986; 6:210–222.
   PubMed Web of Science ®Google Scholar
• Henry JA. Amphetamines. In: Ford MD, Delaney KA, Ling LJ, Erickson T, eds. Clinical Toxicology. Philadelphia, PA: Saunders Company; 2001:620–626.
   Google Scholar
• McKinney PE, Palmer RB. Amphetamines and derivatives. In: Brent J, Wallace KL, Burkhart KK, Phillips SD, Donovan JW, eds. Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient. Philadelphia, PA: Elsevier Mosby; 2005:761–766.
   Google Scholar
• Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994; 24:68–76.
   Google Scholar
• Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med 2010; 56:392–401.
   PubMed Web of Science ®Google Scholar
• Shah AS, Eddleston M. Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures? Clin Toxicol (Phila) 2010; 48:800–805.
   PubMed Web of Science ®Google Scholar
• Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 8: advanced challenges in resuscitation: section 2: toxicology in ECC. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000; 102:1223–1228.
   Google Scholar
• Chiang WK. Amphetamines. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland M, Lewin NA, Nelson LS, eds. Goldfrank’s Toxicologic Emergencies.8th ed. New York: McGraw-Hill; 2006:1118–1132.
   Google Scholar
• Richards DA, Tuckman J, Prichard BN. Assessment of alpha-adrenoceptor and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol 1976; 3:849–855.
   PubMed Web of Science ®Google Scholar
• Greene SL, Kerr F, Braitberg G. Review article: amphetamines and related drugs of abuse. Emerg Med Australas 2008; 20:391–402.
   PubMed Web of Science ®Google Scholar
• Hall AP, Henry JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006; 96:678–685.
   PubMed Web of Science ®Google Scholar
• Rusniak DE, Sprague JE. Hyperthermic syndromes induced by toxins. Clin Lab Med 2006; 26:165–184.
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112–1120.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 2007; 187:361–365.
   PubMed Web of Science ®Google Scholar
• Chan BS, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG. Serotonin syndrome resulting from drug interactions. Med J Aust 1998; 169:523–525.
   PubMed Web of Science ®Google Scholar
• Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis – an overview for clinicians. Crit Care 2005; 9:158–169.
   PubMed Web of Science ®Google Scholar
• Bosch X, Poch E, Grau JM. Current concepts: rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361:62–72.
   PubMed Web of Science ®Google Scholar